Not all leaders are good leaders.Perhaps you’ve lost an important executive or you’re establishing a local leadership team. You know that the leader you choose will have a major impact on the organization. So how can you avoid hiring the…
HOME > BUSINESS
BUSINESS
- Santen Pharmaceutical Apr-Dec Sales Up 5.3% on Steady Growth in Japan and Abroad
February 8, 2012
- Novartis President Mitani Says Diovan Patent Expiry an “Urgent Issue”
February 8, 2012
- Novartis Domestic Sales Up 6% Despite Drop in Diovan
February 8, 2012
- All-Case PMS for Chugai’s Tarceva for NSCLC Lifted
February 8, 2012
- Janssen Files NDA for Anti-HIV Agent Edurant in Japan
February 8, 2012
- JCR Hopes to Build Delivery Network, Boost Product Promotion in Collaboration with Medipal: Chairman Ashida
February 7, 2012
- DSP President Tada Says Steady Shift to Latuda Seen in US
February 7, 2012
- JCR to Push Joint Development with GSK, Including New Biopharmaceuticals
February 7, 2012
- Apr-Dec Sales Rise 7.4% due to Vidaza: Nippon Shinyaku
February 7, 2012
- Apr-Dec Sales Up 1.9% Driven by Artz: Kaken
February 7, 2012
- Astellas to Establish New Global Human Resources Committee on April 1
February 7, 2012
- Takeda Announces US Launch of Combination Hypertension Treatment Edarbyclor
February 7, 2012
- Sanofi-aventis Initiates ALOHA 2 Study of Lantus Plus DPP-4 Inhibitors for Type 2 Diabetes
February 7, 2012
- Pfizer Japan to Launch 2 Generic APIs on Feb 8, Total 18 APIs
February 6, 2012
- OncoTherapy to Jointly Initiate PIII Study for OCV-C01 with Otsuka
February 6, 2012
- US, European Pharmaceutical Companies Supported by Steady Japan Business Growth
February 6, 2012
- Lipitor Generics Have Over 6% of Negative Impact: Astellas
February 6, 2012
- Pfizer Highly Rated for Pharmacist Support: Nextit Research Survey
February 6, 2012
- Mr Tsuchiya of Eisai Disapproves Virtual Permission of Off-label Use of Generics Not Approved for the Same Indications as Their Original Drugs
February 6, 2012
- Chugai Pharmaceutical Dec 2011 Sales Decline After Earthquake Despite Steady Sales Abroad
February 6, 2012
ページ
Earlier this month, Health Minister Keizo Takemi called on the top executives of 13 major generic makers to restructure the industry with a product consolidation target of “around five companies per API.” While a variety of restructuring options are conceivable,…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…